Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ayvakit Sprinkle

(Avutometinib)

Phase 3Small molecule

MMemorial Sloan Kettering Cancer Center

This medication combines two drugs that block abnormal proteins in cancer cells, helping to stop or slow the growth and spread of a specific type of ovarian cancer.[1] Ayvakit Sprinkle is currently being investigated across 15 indications[3], with its most advanced program in Phase 3.[1]

Ayvakit Sprinkle is one of 317 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 3.

15

Indications

18

Total Trials

17

Active Trials

316

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerNot yet recruiting

Gynecologic CancerRecruiting

Low-Grade Serous Ovarian CancerRecruiting

Low Grade Ovarian Serous AdenocarcinomaNot yet recruiting

MGMT-Unmethylated GlioblastomaNot yet recruiting

Advanced Colorectal CancerRecruiting

Solid Tumor CancersRecruiting

Pancreatic AdenocarcinomaNot yet recruiting

Non-Small Cell Lung CancerCompleted

Ovarian CancerActive, not recruiting

Pancreatic CancerPreclinical

Not yet recruiting

Gynecologic CancerPhase 2

Recruiting

Low-Grade Serous Ovarian CancerPhase 3

Recruiting

Low Grade Ovarian Serous AdenocarcinomaPhase 2

Not yet recruiting

MGMT-Unmethylated GlioblastomaPhase 1

Not yet recruiting

Advanced Colorectal CancerPhase 2

Recruiting

Solid Tumor CancersPhase 1

Recruiting

Pancreatic AdenocarcinomaPhase 2

Not yet recruiting

Non-Small Cell Lung CancerPhase 2

Completed

Ovarian CancerPhase 2

Active, not recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Divarasib

Paclitaxel or Nab-Paclitaxel

Neladalkib (NVL-655)

Remeron

OOrganon and Co

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Valemetostat Tosylate

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Ovarian Cancer

NCT04625270

Q1 2027

Phase 2Recruiting

Gynecologic Cancer

NCT05787561

Q2 2027

Phase 2Recruiting

Low-Grade Serous Ovarian Cancer

NCT06394804

Q3 2027

Phase 2Recruiting

Thyroid Cancer

NCT06007924

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Completed·VVerastem, Inc.·Phase 2·NCT04620330·90 enrolled

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Recruiting·EEmory University·Phase 2·NCT06495125·50 enrolled

Avutometinib2 trials

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 1/2·NCT06630260·182 enrolled

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07318324·31 enrolled

Low-grade Serous Ovarian Cancer2 trials

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

Recruiting·VVerastem, Inc.·Phase 3·NCT06072781·270 enrolled

Combination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt Setting

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06394804·20 enrolled

Ovarian Cancer1 trial

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Active, not recruiting·VVerastem, Inc.·Phase 2·NCT04625270·225 enrolled

Solid Tumor Cancers1 trial

A Study of Avutometinib for People With Solid Tumor Cancers

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06104488·23 enrolled

10 more indications

Pancreatic Adenocarcinoma1 trial

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Not yet recruiting·WWashington University School of Medicine·Phase 2·NCT07126158·36 enrolled

Gastric Cancer1 trial

Avutometinib and Defactinib in Diffuse Gastric Cancer

Recruiting·—·Phase 2·NCT06487221·27 enrolled

Cutaneous Melanoma1 trial

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Recruiting·UUniversity of Utah·Phase 1/2·NCT06194929·33 enrolled

Glioblastoma1 trial

Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

Active, not recruiting·EEmory University·Phase 1·NCT05798507·14 enrolled

Pancreatic Cancer1 trial

Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma: A Phase IB/II Safety and Efficacy Study

Not yet recruiting·UUniversity of Virginia·Preclinical·NCT07824960·31 enrolled

Advanced Colorectal Cancer1 trial

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06369259·33 enrolled

MGMT-Unmethylated Glioblastoma1 trial

Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas

Not yet recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT07778602·22 enrolled

Low Grade Ovarian Serous Adenocarcinoma1 trial

Open-Label Extension Study to Provide Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Not yet recruiting·VVerastem, Inc.·Phase 2·NCT07747506·2 enrolled

Gynecologic Cancer1 trial

Single Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05787561·40 enrolled

Thyroid Cancer1 trial

Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06007924·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Avutometinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Avutometinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Avutometinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMemorial Sloan Kettering Cancer Center

Related News